The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

AI has demonstrated considerable potential in diabetic foot (DF) management. AI-powered thermal imaging and predictive ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...